198627-85-9

Upstream product

• 1350060-40-0 tert-butyl 4-[(4-hydroxyphenoxy)methyl]piperidine-1-carboxylate 
• 1401098-21-2 tert-butyl 4-((4-(benzyloxy)phenoxy)methyl)piperidine-1-carboxylate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 103-16-2 4-Benzyloxyphenol 

Downstream Products

• 198627-26-8 trans-4-[(1-tert-Butyloxycarbonylpiperidin-4-yl)methyloxy]-1-(4-methoxycarbonylmethylpiperazino)cyclohexane 
• 1401098-09-6 tert-butyl 4-((4-(3-cyanopyridin-4-yl)cyclohex-3-enyloxy)methyl)piperidine-1-carboxylate 
• 1401098-11-0 tert-butyl 4-((4-(3-(trifluoromethyl)pyridin-4-yl)cyclohex-3-enyloxy)methyl)piperidine-1-carboxylate 
• 1401098-16-5 tert-butyl 4-((4-(3-fluoropyridin-4-yl)cyclohex-3-enyloxy)methyl)piperidine-1-carboxylate 
• 1401098-23-4 tert-butyl 4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enyloxy)methyl)piperidine-1-carboxylate 
• 1401097-81-1 tert-butyl 4-((4-(4-(methylsulfonyl)phenyl)cyclohex-3-enyloxy)methyl)piperidine-1-carboxylate 
• 1401097-82-2 isopropyl 4-((4-(4-(methylsulfonyl)phenyl)cyclohex-3-enyloxy)methyl)piperidine-1-carboxylate 
• 1401098-24-5 4-((4-(4-(methylsulfonyl)phenyl)cyclohex-3-enyloxy)methyl)piperidine hydrochloride 

Relevant academic research and scientific papers

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single agent or in combination with one or more pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, or an alpha-glucosidase inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production

The present invention relates to carboxylic acid derivatives of the general formula STR1 in which Ra to Rc, A, B, D, E and X1 to X3 are as defined in claim 1, their tautomers, their stereoisomers including their mixtures, and their salts, in particular their physiologically tolerated salts with inorganic or organic acids or bases, which have useful pharmacological properties, preferably aggregation-inhibiting inhibiting actions, medicaments containing these compounds, their use and processes for their preparation.